Europe PMC

Background Psoriasis is a chronic immune-mediated skin disorder characterized by excessive keratinocyte proliferation and abnormal T-cell activation. Cluster of Differentiation 28 (CD28), a costimulatory protein, plays a crucial role in psoriasis pathophysiology by enhancing T-cell activation and promoting cytokine release.Methods A case-control study was involving 168 newly diagnosed psoriasis patients and 159 healthy control individuals (HC), Genotyping of rs1879877 in promoter of CD28 gene wa

Assessing disease activity in psoriatic arthritis (PsA) remains challenging, and additional biomarkers that can complement conventional inflammatory markers are still needed. The CRP-albumin-lymphocyte (CALLY) index integrates inflammatory, immune, and nutritional components into a single measure. This study examined the relationship between the CALLY index and disease activity in patients with PsA. This retrospective longitudinal cohort study included 150 patients with PsA and 50 age- and sex-m

Abstract Psoriasis is a chronic immune-mediated disease driven by interacting pro-inflammatory, angiogenic, and regulatory cytokine pathways. While individual cytokines of the IL-23/Th17 and Th1 axes have been widely studied, less is known about how multiple mediators behave collectively in relation to clinical severity. This study evaluated the integrated serum profile of IL-17A, IL-22, TNF-α, VEGF-A, IL-12(p40), and IL-10 in 34 patients with chronic plaque psoriasis and 19 matched healthy con

Psoriasis is a chronic autoinflammatory skin disease lacking curative options. Ronomilast is a novel PDE4i inhibitor with potent anti-inflammatory properties. To evaluate the therapeutic efficacy of topical ronomilast, alone and combined with clobetasol, in an imiquimod (IMQ)-induced psoriasis mouse model. Fifty BALB/c male albino mice were randomly assigned to five groups (n = 10): healthy control, imiquimod-induced, clobetasol-treated (0.05%), ronomilast-treated (0.3%), and combination-treated

Introduction Psoriasis imposes a substantial clinical and quality-of-life burden across the Asia-Pacific (APAC) region. Despite advances in systemic therapies, variability in disease severity classification, assessment tools, and treatment escalation criteria continues to contribute to undertreatment and delayed access to effective care.Methods A modified Delphi panel was conducted to develop APAC-contextualised consensus recommendations for psoriasis management. Statements were generated from a

Introduction Topical therapy plays an essential role in psoriasis management. However, lack of rapid improvement may negatively impact adherence. The calcipotriol and betamethasone dipropionate (CAL/BDP) cream based on polyaphron dispersion (PAD) technology has demonstrated high efficacy, favorable safety, and convenience compared with CAL/BDP gel in phase III trials. This post-hoc analysis aims to assess early treatment response to CAL/BDP PAD-cream at Week (W) 4.Methods This was a post-hoc poo

Psoriasis is a chronic skin disease driven by skin inflammation and abnormal subcutaneous blood vessels. Yinxie Granules (YXKL) is a clinically effective traditional Chinese medicine (TCM) formula that has shown promise in psoriasis treatment, but its pharmacological mechanisms and material basis remain unclear, limiting its clinical application and co-administration with other drugs. In this study, we explored the mechanism and active components of YXKL in the treatment of psoriasis using patie

Background Psoriasis is a chronic immune-mediated inflammatory disease associated with heightened cardiovascular risk. Platelets are increasingly implicated in this link through their capacity to amplify vascular inflammation and interact with leukocytes. Circulating leukocyte-platelet aggregates are elevated in psoriasis, although the biological significance of these aggregates remains incompletely understood. We investigated whether increased leukocyte-platelet aggregates is associated with al

Male genital psoriasis (mGP) is an inflammatory dermatosis affecting the penis and scrotum, a common but significantly under-reported manifestation of psoriasis. Owing to the unique anatomical and microenvironmental characteristics of the male genital region, mGP differs from chronic plaque psoriasis in its clinical presentation, exacerbating factors and therapeutic considerations. Similar to other forms of psoriasis, mGP carries a substantial psychosocial burden. This is amplified by the intima

Objectives To determine the frequency and baseline characteristic differences of complex-to-manage (C2M), difficult-to-manage (D2M) and treatment-refractory (TR) psoriatic arthritis (PsA) in a real-world longitudinal cohort, using the recently proposed 2025 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) definitions.Methods We analysed data from newly diagnosed, disease-modifying antirheumatic drug

We report a case of a 17-year-old girl diagnosed with several severe dermatological conditions: atopic dermatitis (AD), inverse and scalp psoriasis, pustular acne, and hidradenitis suppurativa (HS). We consider this case of particular interest because it is therapeutically challenging and because of its psychological impact on the patient's quality of life. We believe that this case may be useful in understanding the management of complex dermatoses as inescapable from the overall assessment of

Background The efficacy of interleukin-17 inhibitors may be impacted by baseline psoriasis features.Objective This post hoc analysis aimed to explore the efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis stratified by diverse disease features.Methods This post hoc analysis used data from a phase III trial (NCT04839016); 690 patients with moderate-to-severe plaque psoriasis receiving vunakizumab (n = 461) or placebo (n = 229) were included.Results The proportions of pat

Obesity impacts both the clinical management and therapeutic strategies for psoriasis. This study aims to describe the use of biological medicines in treating obese patients with moderate-to-severe psoriasis. We conducted a retrospective cohort study (2007-2022) of obese patients who initiated biological treatments for moderate-severe psoriasis. The primary outcome was the number of biological treatment lines required to achieve an optimal or adequate Psoriasis Area and Severity Index (PASI) sco

Introduction Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic inflammatory conditions treated with primarily immune-modulating medication. However, interest is growing in gut microbiome therapies. Studies have reported altered gut microbiota in PsO/PsA and explored probiotics and fecal microbiota transplantation (FMT) as potential therapies. This review synthesizes global studies on the microbiome's associations in PsO/PsA.Methods We conducted a scoping literature review to understand t

Psoriasis is a chronic, immune-mediated inflammatory disease with heterogeneous manifestations. Reliable biomarkers reflecting disease severity and treatment response remain limited. Glycans-carbohydrate structures attached to proteins and lipids-play key roles in biological processes, contributing to functional specificity. Abnormal glycosylation has been implicated in the pathogenesis of inflammatory and neoplastic diseases, highlighting their potential as therapeutic targets and biomarkers. T

Background Psoriatic arthritis (PsA) is an inflammatory condition involving joints, tendon-bone entheses and synovium that can develop in individuals with psoriasis. Early, accurate clinical diagnosis remains difficult. Extracellular vesicles (EVs) carry proteins and miRNAs that Methods PubMed and Embase were searched from inception through May 21st, 2026, and human studies examining EV-associated protein or miRNA biomarkers in PsA and related psoriatic or inflammatory diseases were included

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Psoriasis is a chronic systemic inflammatory skin disorder that is strongly associated with metabolic disorders, including obesity, insulin resistance, hypertension, and dyslipidemia. Dyslipidemia causes abnormalities in lipid profiles, such as elevated triglycerides or low density lipoprotein (LDL) levels. Measure maternally expressed gene 3 (MEG3) and microRNA-147b in serum of patients with and without dyslipidemia compared to healthy control. These measurements were compared with clinical cha

Although post-translational modifications (PTMs) significantly influence the pathogenesis of psoriasis, their specific mechanisms remain poorly understood. This study aimed to identify novel PTM-targeted therapeutic avenues for the precision treatment of psoriasis. Nine psoriasis-related datasets GSE13355, GSE14905, GSE30999, GSE41664, GSE51440, GSE53552, GSE54456, GSE117239, and GSE226244 were obtained. Consensus clustering was performed to identify psoriasis subtypes. Then, the study proceeded

Background and aims Lipid dysregulation plays a crucial role in psoriasis pathogenesis and its cardiometabolic comorbidities. Novel anthropometric indices such as Body Roundness Index (BRI), Lipid Accumulation Product (LAP), and Triglyceride-Glucose (TyG) index have been proposed to better reflect underlying metabolic dysfunction and may be associated with psoriasis risk, severity, and related complications. This systematic review evaluates the current evidence on the associations of BRI, LAP, a

Drug exposure is one of the potential mechanisms implicated in the onset or exacerbation of psoriasis. To date, several cardiovascular agents have been implicated. Sacubitril/valsartan (SV) has been widely used in the treatment of hypertension and heart failure (HF). Its common adverse reactions include angioedema, hypotension, renal impairment, and hyperkalemia. However, SV may cause psoriasis, which needs clinical attention. This report describes a case of a middle-aged male patient who develo

High-impact site plaque psoriasis is difficult to treat. Icotrokinra, an oral peptide with high specificity for the interleukin (IL)-23 receptor, demonstrated significantly higher rates of high-impact site psoriasis clearance, versus placebo, with no safety signals, through Week (W)16. Report clinical response rates and safety through 1 year of icotrokinra treatment in participants with high-impact site plaque psoriasis. Participants (≥12 years of age; psoriasis body surface area ≥1%; Investigat

Subclinical inflammation (SI) is clinically relevant in psoriasis (PsO) and psoriatic arthritis (PsA), but quantitative imaging biomarkers are lacking. We evaluated the feasibility of ultrashort echo time (UTE) bicomponent MRI for quantifying Achilles enthesis SI. Conventional MRI showed no group differences, whereas short T2* (T2*s) values were significantly elevated in PsO/PsA compared with healthy volunteers. These findings support the feasibility of UTE bicomponent analysis, as a promising t

Activated mast cells (MCs) are crucial effectors in the initiation and progression of psoriasis by secreting inflammatory mediators. The MC activation mediated by Mas-related G-protein-coupled receptor X2 (MrgprX2) has been implicated in psoriasis progression. However, the therapeutic strategies targeting MrgprX2 for psoriasis treatment remain less explored. Alkannin (Alk) is the main active component of the plant Arnebia euchroma and exhibits significant anti-inflammatory activities. However, i